IL6 and chronic kidney disease: After acute paricalcitol supplementation, there is a significant reduction in plasmatic and urinary NGAL values and in IL-17, IL-6, IL-1β, TNF-α, and IFN-γ levels in CKD patients; values return to a normal range.